GLP-1 Availability Shifts: FDA Actions Impact Compounded Wegovy and Ozempic After Removal From Drug Shortage List

2026 FDA & compounding update

Semaglutide Shortage Ended: What FDA Rules Mean Now

The semaglutide injection shortage was declared resolved in February 2025. The temporary shortage-based enforcement-discretion periods have ended, and pharmacies can no longer routinely rely on shortage status to make copies of Wegovy or Ozempic.

Medically reviewed by Dr. Timothy Mackey
Medical Director · Updated September 2026

What changed after February 2025?

FDA concluded that manufacturers could meet present and projected national demand for semaglutide injections. The agency acknowledged that localized supply disruptions could still occur, but it no longer considered the national shortage ongoing.

To reduce disruption, FDA temporarily exercised enforcement discretion for certain shortage-dependent compounding activity. That temporary window has now expired.

What does “shortage resolved” mean for 503A pharmacies?

Section 503A generally requires patient-specific compounding based on a valid prescription and restricts pharmacies and physicians from compounding drugs that are essentially copies of commercially available products regularly or in inordinate amounts.

FDA’s current policy focuses on whether the compounded product has the same active ingredient, a same or easily substitutable strength, and the same route of administration as a commercially available product. A prescriber-documented change that produces a significant clinical difference for an identified patient can matter.

Does adding B12 automatically make compounded semaglutide different?

No. FDA specifically states that adding another active ingredient such as vitamin B12 does not automatically prevent a compounded drug from being considered essentially a copy. If the formulation is substantially the same in clinically relevant respects, merely adding B12 is not enough by itself.

Any claimed difference should be tied to a genuine individualized clinical need rather than used as a marketing workaround.

What does the rule mean for 503B outsourcing facilities?

503B outsourcing facilities face different restrictions. They generally may use bulk drug substances only when the substance appears on the 503B bulks list or when the compounded drug is on FDA’s shortage list at the relevant time.

Semaglutide does not currently appear on the FDA drug-shortage list or the 503B bulks list. In April 2026, FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list after concluding it had not identified a clinical need for outsourcing facilities to compound them from bulk substances.

Is compounded semaglutide FDA-approved?

No. Compounded semaglutide is not FDA-approved and should not be marketed as generic Wegovy or generic Ozempic. It does not undergo the same FDA premarket review for safety, effectiveness, manufacturing quality and labeling.

FDA also stated in 2026 that marketers of non-FDA-approved compounded GLP-1 drugs cannot make misleading claims that those products are the same as or generic versions of FDA-approved products.

Can a 503A pharmacy still make semaglutide for a specific patient?

Potentially, when all applicable federal and state requirements are met and the prescription reflects an actual individualized need. That is different from routine, large-scale production of a near-identical substitute for Wegovy or Ozempic.

The legal analysis is fact-specific, so patients should understand why a compounded preparation is being prescribed and how it differs in a clinically meaningful way for them.

What about very small amounts of “copy” compounding?

FDA has stated that, at this time, it generally does not intend to take action solely on the “regularly or in inordinate amounts” restriction when a compounder fills four or fewer prescriptions of a particular essentially-copy product during a calendar month. That is an enforcement policy, not a blanket approval of the product, and all other applicable requirements still matter.

Are Wegovy and Ozempic interchangeable?

No. Both contain semaglutide, but they are different FDA-approved products with different labeled indications and dosing. Wegovy is the semaglutide brand used for chronic weight management in eligible patients and has additional cardiovascular labeling. Ozempic is primarily indicated for type 2 diabetes with additional cardiovascular and kidney-related indications in appropriate patients.

Patients should not be told that compounded semaglutide is simply “the generic version” of either product.

What happened to the old grace periods?

FDA’s 503A semaglutide enforcement-discretion period ended in April 2025. For 503B outsourcing facilities, the corresponding period ended May 22, 2025.

Those expired dates should no longer be presented as if they are current options.

Does the end of the shortage mean semaglutide is always easy to find?

No. FDA can consider the national shortage resolved even if individual pharmacies occasionally experience delays or localized supply disruptions. National shortage status and local inventory are not the same thing.

Patients unable to locate an FDA-approved product should discuss availability, insurance and legally appropriate alternatives with the prescriber rather than assuming any compounded copy is automatically permitted.

What should patients ask a clinic or pharmacy in 2026?

• Is this prescription for FDA-approved Wegovy or Ozempic, or is it compounded?
• If compounded, why is compounding clinically necessary for this individual patient?
• Which pharmacy is dispensing the medication?
• Is the pharmacy operating under section 503A or as a 503B outsourcing facility?
• How does the formulation differ from a commercially available product?
• Has the prescriber documented a clinically significant difference when required?
• What is the full monthly price, including higher doses, shipping, visits and fees?

Why this page remains separate from our semaglutide treatment page

This article is intentionally focused on FDA shortage history, compounding policy and regulatory status. For eligibility, dosing, efficacy, side effects and treatment considerations, see our dedicated semaglutide for weight loss page.

Frequently asked questions

Is semaglutide still on the FDA shortage list?

No. FDA determined the semaglutide injection shortage was resolved in February 2025.

Can compounding pharmacies still make semaglutide?

Some individualized 503A compounding may still be permissible when legal requirements are satisfied, but pharmacies cannot rely on the former shortage status to routinely make essentially identical copies of FDA-approved semaglutide products.

Is compounded semaglutide generic Wegovy?

No. Compounded semaglutide is not an FDA-approved generic equivalent of Wegovy or Ozempic.

Does adding B12 make compounded semaglutide automatically legal?

No. FDA has specifically cautioned that adding B12 or making a small formulation change does not automatically prevent a compounded product from being considered essentially a copy.

Can local pharmacies still run out of Wegovy even though the shortage is resolved?

Yes. Localized supply disruptions can occur even when FDA no longer considers there to be a national shortage.

Regulatory sources

• FDA: GLP-1 supply and compounding policy updates
• FDA: Compounding when drugs are on the shortage list
• FDA: Enforcement and marketing of non-FDA-approved GLP-1 drugs
• FDA: Proposed exclusion from the 503B bulks list

This article is educational and summarizes federal regulatory developments as of September 2026. Compounding law is fact-specific and may change.